Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines

Cancer Letters

Volumn 331, Issue 2, 2013, Pages 200-210

  Hartmann, Susanne ^a   Günther, Nadine ^a   Biehl, Marlene ^a   Katzer, Astrid ^a   Kuger, Sebastian ^a   Worschech, Eike ^a   Sukhorukov, Vladimir L ^a   Krohne, Georg ^a   Zimmermann, Heiko ^b   Flentje, Michael ^a   Djuzenova, Cholpon S ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Actin remodeling; Cell adhesion; Cell matrix; Hypoxia; Radiation; Stress fibers

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; F ACTIN; FOCAL ADHESION KINASE; HEAT SHOCK PROTEIN 90 INHIBITOR; INTEGRIN LINKED KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NVP BEP800; OXYGEN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; GLIOBLASTOMA; HYPOXIA; IMMUNOFLUORESCENCE; IONIZING RADIATION; LUNG CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCANNING ELECTRON MICROSCOPY; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; FLOW CYTOMETRY; GLIOBLASTOMA; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; LUNG NEOPLASMS; MICROSCOPY, ELECTRON, SCANNING; NEOPLASM INVASIVENESS; PYRIMIDINES; RESORCINOLS; WOUND HEALING;

EID: 84875371704     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.12.027     Document Type: Article

References (43)

1. Fidler I.J. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 1990, 50:6130-6138.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
3. Koga F., Kihara K., Neckers L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res. 2009, 29:797-807.
4. Taiyab A., Rao C.M. Hsp90 modulates actin dynamics: Inhibition of HSP90 leads to decreased cell motility and impairs invasion. Biochim. Biophys. Acta 1813, 2011:213-221.
5. Eiseman J.L., Lan J., Lagattuta T.F., Hamburger D.R., Joseph E., Covey J.M., Egorin M.J. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol. 2005, 55:21-32.
6. Eccles S.A., Massey A., Raynaud F.I., Sharp S.Y., Box G., Valenti M., Patterson L., de Haven Brandon A., Gowan S., Boxall F., Aherne W., Rowlands M., Hayes A., Martins V., Urban F., Boxall K., Prodromou C., Pearl L., James K., Matthews T.P., Cheung K.M., Kalusa A., Jones K., McDonald E., Barril X., Brough P.A., Cansfield J.E., Dymock B., Drysdale M.J., Finch H., Howes R., Hubbard R.E., Surgenor A., Webb P., Wood M., Wright L., Workman P. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008, 68:2850-2860.
7. Kelland L.R., Sharp S.Y., Rogers P.M., Myers T.G., Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. 1999, 91:1940-1949.
8. Brough P.A., Aherne W., Barril X., Borgognoni J., Boxall K., Cansfield J.E., Cheung K.M., Collins I., Davies N.G., Drysdale M.J., Dymock B., Eccles S.A., Finch H., Fink A., Hayes A., Howes R., Hubbard R.E., James K., Jordan A.M., Lockie A., Martins V., Massey A., Matthews T.P., McDonald E., Northfield C.J., Pearl L.H., Prodromou C., Ray S., Raynaud F.I., Roughley S.D., Sharp S.Y., Surgenor A., Walmsley D.L., Webb P., Wood M., Workman P., Wright L. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J. Med. Chem. 2008, 51:196-218.
9. Gao Z., Garcia-Echeverria C., Jensen M.R. Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. Curr. Opin. Drug Discov. Devel. 2010, 13:193-202.
10. Brough P.A., Barril X., Borgognoni J., Chene P., Davies N.G., Davis B., Drysdale M.J., Dymock B., Eccles S.A., Garcia-Echeverria C., Fromont C., Hayes A., Hubbard R.E., Jordan A.M., Jensen M.R., Massey A., Merrett A., Padfield A., Parsons R., Radimerski T., Raynaud F.I., Robertson A., Roughley S.D., Schoepfer J., Simmonite H., Sharp S.Y., Surgenor A., Valenti M., Walls S., Webb P., Wood M., Workman P., Wright L. Combining hit identification strategies: Fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the hsp90 molecular chaperone. J. Med. Chem. 2009, 52:4794-4809.
11. Massey A.J., Schoepfer J., Brough P.A., Brueggen J., Chene P., Drysdale M.J., Pfaar U., Radimerski T., Ruetz S., Schweitzer A., Wood M., Garcia-Echeverria C., Jensen M.R. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. Mol. Cancer Ther. 2010, 9:906-919.
12. Stingl L., Stuhmer T., Chatterjee M., Jensen M.R., Flentje M., Djuzenova C.S. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br. J. Cancer 2010, 102:1578-1591.
13. Niewidok N., Wack L.-J., Schiessl S., Stingl L., Katzer A., Polat B., Sukhorukov V.L., Flentje M., Djuzenova C.S. Hsp90 inhibitors, NVP-AUY922 and NVP-BEP800 may exert a significant radiosensitization on tumor cells along with a cell type-specific cytotoxicity. Transl. Oncol. 2012, 5:356-369.
14. Djuzenova C.S., Blassl C., Roloff K., Kuger S., Katzer A., Niewidok N., Günther N., Polat B., Sukhorukov V.L., Flentje M. Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia. Cancer Biol. Ther. 2012, 13:425-434.
15. Koll T.T., Feis S.S., Wright M.H., Teniola M.M., Richardson M.M., Robles A.I., Bradsher J., Capala J., Varticovski L. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol. Cancer Ther. 2008, 7:1985-1992.
16. Robles A.I., Wright M.H., Gandhi B., Feis S.S., Hanigan C.L., Wiestner A., Varticovski L. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin. Cancer Res. 2006, 12:6547-6556.
17. Gassert E., Avota E., Harms H., Krohne G., Gulbins E., Schneider-Schaulies S. Induction of membrane ceramides: a novel strategy to interfere with T lymphocyte cytoskeletal reorganisation in viral immunosuppression. PLoS Pathog. 2009, 5:e1000623.
18. Ulyatt C., Walker J., Ponnambalam S. Hypoxia differentially regulates VEGFR1 and VEGFR2 levels and alters intracellular signaling and cell migration in endothelial cells. Biochem. Biophys. Res. Commun. 2011, 404:774-779.
19. Megison M.L., Stewart J.E., Nabers H.C., Gillory L.A., Beierle E.A. FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma. Clin. Exp. Metastasis 2012, (Dec 4). [Epub ahead of print].
20. Schlaepfer D.D., Hauck C.R., Sieg D.J. Signaling through focal adhesion kinase. Progr. Biophys. Mol. Biol. 1999, 71:435-478.
21. Frisch S.M., Vuori K., Ruoslahti E., Chan-Hui P.Y. Control of adhesion-dependent cell survival by focal adhesion kinase. J. Cell Biol. 1996, 134:793-799.
22. Sonoda Y., Matsumoto Y., Funakoshi M., Yamamoto D., Hanks S.K., Kasahara T. Anti-apoptotic role of focal adhesion kinase (FAK), Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J. Biol. Chem. 2000, 275:16309-16315.
23. Bristow R.G., Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 2008, 8:180-192.
24. 13 stimulate Rho-dependent stress fiber formation and focal adhesion assembly. J. Biol. Chem. 1995, 270:24631-24634.
25. Picard D. Heat-shock protein 90, a chaperone for folding and regulation. Cell Mol. Life Sci. 2002, 59:1640-1648.
26. Ochel H.J., Schulte T.W., Nguyen P., Trepel J., Neckers L. The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase. Mol. Genet. Metab. 1999, 66:24-30.
27. Aoyagi Y., Fujita N., Tsuruo T. Stabilization of integrin-linked kinase by binding to Hsp90. Biochem. Biophys. Res. Commun. 2005, 331:1061-1068.
28. Troussard A.A., Costello P., Yoganathan T.N., Kumagai S., Roskelley C.D., Dedhar S. The integrin linked kinase. Oncogene 2000, 19:5444-5452.
29. Hashiramoto A., Murata M., Kawazoe T., Yoshida K., Akiyama C., Shiozawa K., Shiozawa S. Heat shock protein 90 maintains the tumour-like character of rheumatoid synovial cells by stabilizing integrin-linked kinase, extracellular signal-regulated kinase and protein kinase B. Rheumatology (Oxford) 2011, 50:852-861.
30. Huang C., Jacobson K., Schaller M.D. MAP kinases and cell migration. J. Cell Sci. 2004, 117:4619-4628.
31. Srinivasan R., Zabuawala T., Huang H., Zhang J., Gulati P., Fernandez S., Karlo J.C., Landreth G.E., Leone G., Ostrowski M.C. Erk1 and Erk2 regulate endothelial cell proliferation and migration during mouse embryonic angiogenesis. PLoS One 2009, 4:e8283.
32. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., Lehmann B., Terrian D.M., Milella M., Tafuri A., Stivala F., Libra M M., Basecke J., Evangelisti C., Martelli A.M., Franklin R.A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007, 1773:1263-1284.
33. Etienne-Manneville S., Hall A. Rho GTPases in cell biology. Nature 2002, 420:629-635.
34. Meng X.N., Jin Y., Yu Y., Bai J., Liu G.Y., Zhu J., Zhao Y.Z., Wang Z., Chen F., Lee K.Y., Fu S.B. Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br. J. Cancer 2009, 101:327-334.
35. Gen Y., Yasui K., Zen K., Nakajima T., Tsuji K., Endo M., Mitsuyoshi H., Minami M., Itoh Y., Tanaka S., Taniwaki M., Arii S., Okanoue T., Yoshikawa T. A novel amplification target, ARHGAP5, promotes cell spreading and migration by negatively regulating RhoA in Huh-7 hepatocellular carcinoma cells. Cancer Lett. 2009, 275:27-34.
36. Amiri A., Noei F., Feroz T., Lee J.M. Geldanamycin anisimycins activate Rho and stimulate Rho- and ROCK-dependent actin stress fiber formation. Mol. Cancer Res. 2007, 5:933-942.
37. Amano M., Chihara K., Kimura K., Fukata Y., Nakamura N., Matsuura Y., Kaibuchi K. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 1997, 275:1308-1311.
38. Sandfort V., Eke I., Cordes N. The role of the focal adhesion protein pinch1 for the radiosensitivity of adhesion and suspension cell cultures. PLoS One 2010, 5:e13056.
39. Obara S., Nakata M., Takeshima H., Kuratsu J., Maruyama I., Kitajima I. Inhibition of migration of human glioblastoma cells by cerivastatin in association with focal adhesion kinase (FAK). Cancer Lett. 2002, 28:153-161.
40. Flandrin-Gresta P., Solly F., Aanei C.M., Cornillon J., Tavernier E., Nadal N., Morteux F., Guyotat D., Wattel E., Campos L. Oncotarget 2012, 3:1158-1168.
41. Zhang H.M., Keledjian K.M., Rao J.N., Zou T., Liu L., Marasa B.S., Wang S.R., Ru L., Strauch E.D., Wang J.Y. Induced focal adhesion kinase expression suppresses apoptosis by activating NF-kB signaling in intestinal epithelial cells. Am. J. Physiol. Cell Physiol. 2006, 290:C1310-C1320.
42. van der Water B., Nagelkerke J.F., Stevens J.L. Dephosphorylation of focal adhesion kinase (FAK) and loss of focal contacts precede caspase-mediated cleavage of FAK during apoptosis in renal epithelial cells. J. Biol. Chem. 1999, 274:13328-13337.
43. Knobbe C.B., Merlo A., Reifenberger G. Pten signaling in gliomas. Neuro-Oncology 2002, 4:196-211.